437 related articles for article (PubMed ID: 12358344)
1. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis.
Hodson ME; Gallagher CG; Govan JR
Eur Respir J; 2002 Sep; 20(3):658-64. PubMed ID: 12358344
[TBL] [Abstract][Full Text] [Related]
2. New clinical evidence from the European tobramycin trial in cystic fibrosis.
Hodson ME; Gallagher CG
J Cyst Fibros; 2002 Dec; 1(Suppl 2):199-202. PubMed ID: 15463835
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Langton Hewer SC; Smyth AR
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD004197. PubMed ID: 28440853
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Langton Hewer SC; Smyth AR
Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937
[TBL] [Abstract][Full Text] [Related]
5. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
[TBL] [Abstract][Full Text] [Related]
6. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
[TBL] [Abstract][Full Text] [Related]
7. Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model.
Tappenden P; Harnan S; Uttley L; Mildred M; Carroll C; Cantrell A
Health Technol Assess; 2013 Dec; 17(56):v-xvii, 1-181. PubMed ID: 24290164
[TBL] [Abstract][Full Text] [Related]
8. The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis.
Tappenden P; Harnan S; Uttley L; Mildred M; Walshaw M; Taylor C; Brownlee K
Pharmacoeconomics; 2014 Feb; 32(2):159-72. PubMed ID: 24338264
[TBL] [Abstract][Full Text] [Related]
9. Insights into cystic fibrosis microbiology from the European tobramycin trial in cystic fibrosis.
Govan JR
J Cyst Fibros; 2002 Dec; 1(Suppl 2):203-8. PubMed ID: 15463836
[TBL] [Abstract][Full Text] [Related]
10. Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis.
Adeboyeku D; Scott S; Hodson ME
J Cyst Fibros; 2006 Dec; 5(4):261-3. PubMed ID: 16807142
[TBL] [Abstract][Full Text] [Related]
11. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
Cheer SM; Waugh J; Noble S
Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
[TBL] [Abstract][Full Text] [Related]
13. Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis.
Uttley L; Harnan S; Cantrell A; Taylor C; Walshaw M; Brownlee K; Tappenden P
Eur Respir Rev; 2013 Dec; 22(130):476-86. PubMed ID: 24293463
[TBL] [Abstract][Full Text] [Related]
14. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis.
Littlewood KJ; Higashi K; Jansen JP; Capkun-Niggli G; Balp MM; Doering G; Tiddens HA; Angyalosi G
J Cyst Fibros; 2012 Sep; 11(5):419-26. PubMed ID: 22717535
[TBL] [Abstract][Full Text] [Related]
15. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
[TBL] [Abstract][Full Text] [Related]
16. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
Al-Aloul M; Nazareth D; Walshaw M
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.
Sommerwerck U; Virella-Lowell I; Angyalosi G; Viegas A; Cao W; Debonnett L
Curr Med Res Opin; 2016 Nov; 32(11):1789-1795. PubMed ID: 27435882
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS.
Sands D; Sapiejka E; Gąszczyk G; Mazurek H;
J Cyst Fibros; 2014 Dec; 13(6):653-60. PubMed ID: 24836961
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.
Mazurek H; Chiron R; Kucerova T; Geidel C; Bolbas K; Chuchalin A; Blanco-Aparicio M; Santoro D; Varoli G; Zibellini M; Cicirello HG; Antipkin YG
Pediatr Pulmonol; 2014 Nov; 49(11):1076-89. PubMed ID: 24464974
[TBL] [Abstract][Full Text] [Related]
20. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
